PriceTargets.com logo

FibroGen - FGEN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $17.00
  • Forecasted Upside: 1,316.67%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.20 As of 05/17/2024 01:00 AM ET
▼ -0.04 (-3.23%)

This chart shows the closing price for FGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New FibroGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FGEN

Analyst Price Target is $17.00
▲ +1,316.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $17.00, with a high forecast of $32.00 and a low forecast of $2.00. The average price target represents a 1,316.67% upside from the last price of $1.20.

This chart shows the closing price for FGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 4 investment analysts is to reduce stock in FibroGen. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2024William BlairReiterated RatingMarket PerformLow
8/8/2023Bank of AmericaDowngradeNeutral ➝ Underperform$4.00 ➝ $2.00Low
6/26/2023Stifel NicolausDowngradeBuy ➝ HoldN/A
6/26/2023Bank of AmericaDowngradeBuy ➝ NeutralN/A
6/26/2023Raymond JamesDowngradeOutperform ➝ Market PerformN/A
6/26/2023William BlairDowngradeOutperform ➝ Market PerformN/A
6/1/2023Stifel NicolausUpgradeHold ➝ Buy$23.00 ➝ $32.00Low
2/28/2023CowenBoost TargetMarket Perform$15.00 ➝ $25.00Low
2/21/2023The Goldman Sachs GroupBoost TargetSell$9.00 ➝ $16.00Low
1/30/2023William BlairUpgradeMarket Perform ➝ OutperformLow
1/26/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$35.00Low
1/5/2023Bank of AmericaUpgradeNeutral ➝ Buy$18.00 ➝ $27.00Low
8/15/2022CowenBoost Target$14.00N/A
5/24/2022The Goldman Sachs GroupLower TargetSell$9.00 ➝ $8.00High
3/1/2022The Goldman Sachs GroupLower TargetSell$10.00 ➝ $9.00High
9/22/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$16.00 ➝ $11.00High
8/20/2021Raymond JamesUpgradeUnderperform ➝ Market PerformMedium
8/11/2021The Goldman Sachs GroupBoost TargetNeutral$16.00 ➝ $22.00Low
8/10/2021SVB LeerinkLower TargetPositive ➝ Outperform$35.00 ➝ $30.00Low
7/16/2021SVB LeerinkReiterated RatingOutperform$56.00 ➝ $35.00High
7/16/2021CowenLower TargetMarket Perform$21.00 ➝ $16.00High
7/16/2021MizuhoLower TargetNeutral$32.00 ➝ $18.00High
7/16/2021Bank of AmericaDowngradeBuy ➝ Neutral$29.00High
7/16/2021Stifel NicolausDowngradeBuy ➝ Hold$55.00 ➝ $29.00High
6/28/2021MizuhoBoost TargetPositive ➝ Neutral$29.00 ➝ $32.00Low
4/13/2021HC WainwrightReiterated RatingBuy ➝ NeutralN/A
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$29.00N/A
4/7/2021JPMorgan Chase & Co.UpgradeNeutralHigh
4/7/2021SVB LeerinkLower TargetOutperform$64.00 ➝ $56.00High
4/7/2021Raymond JamesReiterated RatingSellHigh
4/7/2021MizuhoDowngradeBuy ➝ Neutral$72.00 ➝ $29.00High
4/7/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
3/31/2021Bank of AmericaUpgradeNeutral ➝ Buy$47.00High
3/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$75.00 ➝ $45.00N/A
3/2/2021SVB LeerinkLower TargetOutperform$91.00 ➝ $64.00High
3/2/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$75.00 ➝ $45.00High
2/1/2021HC WainwrightInitiated CoverageBuy$58.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$90.00 ➝ $92.00Low
10/26/2020Raymond JamesInitiated CoverageUnderperformHigh
9/8/2020SVB LeerinkBoost TargetOutperform$84.00 ➝ $90.00Low
8/7/2020SVB LeerinkBoost TargetOutperform$80.00 ➝ $84.00High
5/11/2020MizuhoReiterated RatingBuyHigh
5/8/2020SVB LeerinkLower TargetOutperform$85.00 ➝ $80.00Low
5/1/2020CowenInitiated CoverageMarket Perform$40.00High
4/27/2020Bank of AmericaInitiated CoverageNeutral$45.00Low
4/20/2020MizuhoReiterated RatingBuy$72.00High
3/19/2020CitigroupLower TargetBuy$65.00 ➝ $51.00High
2/13/2020MizuhoReiterated RatingBuy$72.00High
11/18/2019MizuhoReiterated RatingBuy$72.00Low
11/11/2019MizuhoReiterated RatingBuy ➝ Positive$65.00 ➝ $72.00High
8/26/2019MizuhoReiterated RatingBuy$65.00Medium
8/11/2019MizuhoReiterated RatingBuy$65.00High
7/2/2019William BlairReiterated RatingHoldLow
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$45.00Low
5/27/2019Piper Sandler CompaniesReiterated RatingNeutral ➝ Positive$65.00 ➝ $40.00Low
(Data available from 5/19/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
2/19/2024
  • 9 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/19/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/19/2024

Current Sentiment

  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $1.20
Low: $1.20
High: $1.33

50 Day Range

MA: $1.59
Low: $0.98
High: $2.64

52 Week Range

Now: $1.20
Low: $0.33
High: $19.47

Volume

1,307,397 shs

Average Volume

3,136,110 shs

Market Capitalization

$119.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of FibroGen?

The following Wall Street analysts have issued research reports on FibroGen in the last year: Bank of America Co., Raymond James, Stifel Nicolaus, StockNews.com, and William Blair.
View the latest analyst ratings for FGEN.

What is the current price target for FibroGen?

2 Wall Street analysts have set twelve-month price targets for FibroGen in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 1,316.7%. Stifel Nicolaus has the highest price target set, predicting FGEN will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $2.00 for FibroGen in the next year.
View the latest price targets for FGEN.

What is the current consensus analyst rating for FibroGen?

FibroGen currently has 1 sell rating and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for FGEN.

What other companies compete with FibroGen?

Other companies that are similar to FibroGen include Adagene, Immunic, Abeona Therapeutics, Rezolute and Coya Therapeutics. Learn More about companies similar to FibroGen.

How do I contact FibroGen's investor relations team?

FibroGen's physical mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 978-1200 and its investor relations email address is [email protected]. The official website for FibroGen is www.fibrogen.com. Learn More about contacing FibroGen investor relations.